20 January 2021 - Parsortix update
Yet more positive news from AIM-listed ANGLE, which has revealed that its proprietary blood cell separation system Parsortix has been endorsed by researchers at Western University and Lawson Health Research Institute in Ontario, Canada. The Parsortix system continues to gain positive newsflow and although patience may be required we do believe that long term holders of ANGLE shares will be well rewarded. The shares have moved up sharply since dropping below 40p last month. They may now consolidate at these higher levels buy they remain a BUY ON WEAKNESS
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
